Repositioning metformin for cancer prevention and treatment

被引：236
作者：
Quinn, Brendan J. [1 ]
Kitagawa, Hiroshi [1 ]
Memmott, Regan M. [1 ]
Gills, Joell J. [1 ]
Dennis, Phillip A. [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21224 USA
来源：
TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2013年 / 24卷 / 09期
关键词：
metformin; AMPK; cancer; diabetes; chemoprevention; ACTIVATED PROTEIN-KINASE; POLYCYSTIC-OVARY-SYNDROME; CHRONIC HEPATITIS-C; FATTY LIVER-DISEASE; CELL LUNG-CANCER; I IGF-I; INSULIN-RESISTANCE; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; LKB1-AMPK PATHWAY;
D O I：
10.1016/j.tem.2013.05.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Metformin is the most commonly prescribed drug for type 2 diabetes (T2DM). Retrospective studies show that metformin is associated with decreased cancer risk. This historical correlation has driven vigorous research campaigns to determine the anticancer mechanisms of metformin. Consolidating the preclinical data is a challenge because unanswered questions remain concerning relevant mechanisms, bioavailability, and genetic factors that confer metformin sensitivity. Perhaps the most important unanswered question is whether metformin has activity against cancer in non-diabetics. In this review we highlight the proposed mechanisms of metformin action in cancer and discuss ongoing clinical trials with metformin in cancer. Improved understanding of these issues will increase the chances for successful application of metformin as an inexpensive, well-tolerated, and effective anticancer agent.
引用
收藏
页码：469 / 480
页数：12
相关论文
共 107 条
[1]   Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo [J].
Algire, C. ;
Amrein, L. ;
Bazile, M. ;
David, S. ;
Zakikhani, M. ;
Pollak, M. .
ONCOGENE, 2011, 30 (10) :1174-1182
[2]   Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage [J].
Algire, Carolyn ;
Moiseeva, Olga ;
Deschenes-Simard, Xavier ;
Amrein, Lilian ;
Petruccelli, Luca ;
Birman, Elena ;
Viollet, Benoit ;
Ferbeyre, Gerardo ;
Pollak, Michael N. .
CANCER PREVENTION RESEARCH, 2012, 5 (04) :536-543
[3]   Metformin for aging and cancer prevention [J].
Anisimov, Vladimir N. .
AGING-US, 2010, 2 (11) :760-774
[4]   The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis [J].
Ascha, Mustafa S. ;
Hanouneh, Ibrahim A. ;
Lopez, Rocio ;
Tamimi, Tarek Abu-Rajab ;
Feldstein, Ariel F. ;
Zein, Nizar N. .
HEPATOLOGY, 2010, 51 (06) :1972-1978
[5]   TRADITIONAL PLANT MEDICINES AS TREATMENTS FOR DIABETES [J].
BAILEY, CJ ;
DAY, C .
DIABETES CARE, 1989, 12 (08) :553-564
[6]   Insulin sensitizers for polycystic ovary syndrome [J].
Baillargeon, JP ;
Iuorno, MJ ;
Nestler, JE .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2003, 46 (02) :325-340
[7]   The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level [J].
Ben Sahra, I. ;
Laurent, K. ;
Loubat, A. ;
Giorgetti-Peraldi, S. ;
Colosetti, P. ;
Auberger, P. ;
Tanti, J. F. ;
Le Marchand-Brustel, Y. ;
Bost, F. .
ONCOGENE, 2008, 27 (25) :3576-3586
[8]   Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1 [J].
Ben Sahra, Isaam ;
Regazzetti, Claire ;
Robert, Guillaume ;
Laurent, Kathiane ;
Le Marchand-Brustel, Yannick ;
Auberger, Patrick ;
Tanti, Jean-Francois ;
Giorgetti-Peraldi, Sophie ;
Bost, Frederic .
CANCER RESEARCH, 2011, 71 (13) :4366-4372
[9]   An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress [J].
Bonnefont-Rousselot, D ;
Raji, B ;
Walrand, S ;
Gardès-Albert, M ;
Jore, D ;
Legrand, A ;
Peynet, J ;
Vasson, MP .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (05) :586-589
[10]   Insulin Resistance in Nonalcoholic Fatty Liver Disease [J].
Bugianesi, E. ;
Moscatiello, S. ;
Ciaravella, M. F. ;
Marchesini, G. .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) :1941-1951
12345678910